Atossa Therapeutics Last Patient Its Phase 2 Karisma-Endoxifen Clinical Trial Recieved Their Final Dose

5/15/24 8:39:30 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ATOS alert in real time by email

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that the last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Get the next $ATOS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATOS

Date	Price Target	Rating	Analyst

More analyst ratings

$ATOS
Press Releases

Fastest customizable press release news feed in the world

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced that a poster detailing the anti-cancer activity of (Z)-endoxifen-related compounds in estrogen receptor alpha-positive (ERα+) breast cancer will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in Toronto from December 9-11, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The poster, titled "Anti-cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer," explores
11/21/24 8:30:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that five abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), taking place December 10-13, 2024, in San Antonio, Texas. The presentations will showcase significant findings from various studies evaluating the use of (Z)-endoxifen in breast cancer prevention and treatment, including phase 2 trials and innovative combination the
11/20/24 8:30:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12
11/12/24 8:30:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care

$ATOS
Financials

Live finance-specific insights

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023. Second Quarter 2023 Conference Call DetailsDate: Monday, August 14, 2023Time: 9:00 a.m. ET / 6:00 a.m. PTParticipant Registration: https://edge.media-server.com/mmc/p/2qtrmqz3 Interested participants should register for the confere
8/8/23 9:00:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended first quarter 2023 with $103.9 million of cash and cash equivalents and no debt SEATTLE, May 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments. Key de
5/15/23 9:10:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date include: Received FDA authorization from FDA to initiate its Phase 2 study of neoadjuvant (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer. Invested in a privately-held Dynamic Cell T
11/7/22 4:00:00 PM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care

$ATOS
Leadership Updates

Live Leadership Updates

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12
11/12/24 8:30:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial
11/5/24 8:30:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t
8/20/24 8:30:00 AM ET
$ATOS
Biotechnology: Pharmaceutical Preparations
Health Care

Atossa Therapeutics Last Patient Its Phase 2 Karisma-Endoxifen Clinical Trial Recieved Their Final Dose

Chat with this insight

Recent Analyst Ratings for
$ATOS

$ATOS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

$ATOS
Press Releases

Fastest customizable press release news feed in the world

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

$ATOS
Market Insights

Live Market Insights

Atossa Therapeutics Completes Enrollment Of 80mg Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen For ER+ / HER2- Breast Cancer

Atossa Therapeutics Appoints Heather Rees As New CFO

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target

$ATOS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

$ATOS
SEC Filings

Atossa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form 424B5 filed by Atossa Therapeutics Inc.

Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ATOS
Financials

Live finance-specific insights

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

$ATOS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Galli Stephen J

SEC Form 4 filed by Director Steinhart Richard I

SEC Form 4 filed by Director Chen Shu-Chih

$ATOS
Leadership Updates

Live Leadership Updates

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Atossa Therapeutics Last Patient Its Phase 2 Karisma-Endoxifen Clinical Trial Recieved Their Final Dose

Chat with this insight

Recent Analyst Ratings for $ATOS

$ATOS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

$ATOS Press Releases

Fastest customizable press release news feed in the world

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

$ATOS Market Insights

Live Market Insights

Atossa Therapeutics Completes Enrollment Of 80mg Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen For ER+ / HER2- Breast Cancer

Atossa Therapeutics Appoints Heather Rees As New CFO

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target

$ATOS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

$ATOS SEC Filings

Atossa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form 424B5 filed by Atossa Therapeutics Inc.

Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ATOS Financials

Live finance-specific insights

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

$ATOS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Galli Stephen J

SEC Form 4 filed by Director Steinhart Richard I

SEC Form 4 filed by Director Chen Shu-Chih

$ATOS Leadership Updates

Live Leadership Updates

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Recent Analyst Ratings for
$ATOS

$ATOS
Insider Purchases

$ATOS
Press Releases

$ATOS
Market Insights

$ATOS
Large Ownership Changes

$ATOS
SEC Filings

$ATOS
Financials

$ATOS
Insider Trading

$ATOS
Leadership Updates